NASDAQ:ANGN

Angion Biomedica Competitors

$15.48
-0.22 (-1.40 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.06
Now: $15.48
$16.19
50-Day Range
$15.01
MA: $18.99
$25.74
52-Week Range
$12.56
Now: $15.48
$26.30
Volume66,200 shs
Average Volume193,712 shs
Market Capitalization$456.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Angion Biomedica (NASDAQ:ANGN) Vs. BCAB, IMCR, CGEM, EWTX, KNTE, and SBTX

Should you be buying ANGN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Angion Biomedica, including BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Kinnate Biopharma (KNTE), and Silverback Therapeutics (SBTX).

Angion Biomedica (NASDAQ:ANGN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and BioAtla's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Angion BiomedicaN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Angion Biomedica and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Angion BiomedicaN/AN/AN/A
BioAtlaN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and BioAtla, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Angion Biomedica00403.00
BioAtla00403.00

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 22.49%. Given Angion Biomedica's higher possible upside, analysts plainly believe Angion Biomedica is more favorable than BioAtla.

Summary

Angion Biomedica beats BioAtla on 1 of the 1 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and Immunocore's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Angion BiomedicaN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Profitability

This table compares Angion Biomedica and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Angion BiomedicaN/AN/AN/A
ImmunocoreN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Angion Biomedica00403.00
Immunocore01202.67

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 53.18%. Given Angion Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Angion Biomedica is more favorable than Immunocore.

Summary

Angion Biomedica beats Immunocore on 3 of the 3 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares Angion Biomedica and Cullinan Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Angion BiomedicaN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Angion Biomedica and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Angion BiomedicaN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Angion Biomedica and Cullinan Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Angion Biomedica00403.00
Cullinan Oncology01302.75

Angion Biomedica presently has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Cullinan Oncology has a consensus price target of $48.25, indicating a potential upside of 49.38%. Given Angion Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Angion Biomedica is more favorable than Cullinan Oncology.

Summary

Angion Biomedica beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Cricut and Angion Biomedica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CricutN/AN/AN/A
Angion BiomedicaN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Cricut and Angion Biomedica, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cricut0000N/A
Angion Biomedica00403.00

Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Cricut.

Valuation and Earnings

This table compares Cricut and Angion Biomedica's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CricutN/AN/AN/AN/AN/A
Angion BiomedicaN/AN/AN/AN/AN/A

Summary

Angion Biomedica beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kinnate Biopharma and Angion Biomedica, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinnate Biopharma00403.00
Angion Biomedica00403.00

Kinnate Biopharma presently has a consensus target price of $52.00, indicating a potential upside of 64.82%. Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Kinnate Biopharma.

Profitability

This table compares Kinnate Biopharma and Angion Biomedica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kinnate BiopharmaN/AN/AN/A
Angion BiomedicaN/AN/AN/A

Earnings & Valuation

This table compares Kinnate Biopharma and Angion Biomedica's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kinnate BiopharmaN/AN/AN/AN/AN/A
Angion BiomedicaN/AN/AN/AN/AN/A

Summary

Angion Biomedica beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Silverback Therapeutics and Angion Biomedica, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Angion Biomedica00403.00

Silverback Therapeutics currently has a consensus price target of $50.25, indicating a potential upside of 31.99%. Angion Biomedica has a consensus price target of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Angion Biomedica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
Angion BiomedicaN/AN/AN/A

Earnings & Valuation

This table compares Silverback Therapeutics and Angion Biomedica's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
Angion BiomedicaN/AN/AN/AN/AN/A

Summary

Angion Biomedica beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.


Angion Biomedica Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioAtla logo
BCAB
BioAtla
1.5$47.35-0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47-2.3%$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30-5.8%$1.41 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$29.54-1.6%$1.41 billionN/A0.00News Coverage
KNTE
Kinnate Biopharma
1.7$31.55-0.5%$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07-5.4%$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12-9.2%$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02-5.2%$1.19 billionN/A0.00Gap Down
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01-11.1%$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00Analyst Downgrade
Gap Down
PHAR
Pharming Group
0.0$13.26-1.1%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00News Coverage
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44-2.2%$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13-4.7%$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54-0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Down
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89-10.2%$0.00N/A0.00High Trading Volume
SCPS
Scopus BioPharma
1.4$7.57-6.2%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.